Patent classifications
C07D211/24
ArylSulfonamide-based matrix metalloprotease inhibitors
The present invention provides a compound of formula (I): ##STR00001##
said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
L-tartrate salt of pridopidine
The subject invention provides pridopidine L-tartrate, compositions and a process for manufacture thereof.
L-tartrate salt of pridopidine
The subject invention provides pridopidine L-tartrate, compositions and a process for manufacture thereof.
PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE
This invention is related to the field of PCSK9 biology and the composition and methods of use of small organic compounds as ligands for modulation of PCSK9 biological activity. In particular, the invention provides compositions of small organic compounds that modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9. Binding these small organic compound ligands to PCSK9 alters the conformation of the protein, modifying the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for small organic compound ligands that can raise LDL levels.
Spirocyclic ROR-gamma modulators
Described herein are retinoic acid related-related orphan nuclear receptor (ROR) modulators and methods of utilizing ROR-gamma modulators in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.
Spirocyclic ROR-gamma modulators
Described herein are retinoic acid related-related orphan nuclear receptor (ROR) modulators and methods of utilizing ROR-gamma modulators in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.
SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF
Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I):
##STR00001##
wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.
SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF
Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I):
##STR00001##
wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.
COMPOUNDS CONTAINING A SULFONIC GROUP AS KAT INHIBITORS
The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
##STR00001##
COMPOUNDS CONTAINING A SULFONIC GROUP AS KAT INHIBITORS
The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
##STR00001##